Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

dc.contributor.author	Kudo, M.
dc.contributor.author	Rimassa, L.
dc.contributor.author	Chan, S. L.
dc.contributor.author	Sangro, B.
dc.contributor.author	Lau, G.
dc.contributor.author	Breder, V. V.
dc.contributor.author	Varela Calvo, María
dc.contributor.author	(et al.)
dc.date.accessioned	2025-04-30T09:18:59Z
dc.date.available	2025-04-30T09:18:59Z
dc.date.issued	2024
dc.identifier.issn	0923-7534
dc.identifier.issn	1569-8041
dc.identifier.uri	https://hdl.handle.net/10651/78685
dc.description.sponsorship	AstraZeneca
dc.format.extent	p. S1451-S1452
dc.language.iso	eng
dc.relation.ispartof	Annals of Oncology
dc.rights	©,
dc.source	WOS:001401985200121
dc.title	Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
dc.type	conference output
dc.identifier.doi	10.1016/j.annonc.2024.10.151
dc.relation.publisherversion	http://dx.doi.org/10.1016/j.annonc.2024.10.151

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.